Emerging therapeutic targets and strategies in Crohn’s disease

Federica Furfaro, Gionata Fiorino, Mariangela Allocca, Daniela Gilardi, Silvio Danese

Research output: Contribution to journalArticlepeer-review


Crohn’s disease (CD) is an immune-mediated inflammatory bowel disease, in which inflammation is driven by a complex interaction between the microbiota, immune cells, genes and mediators. New mechanisms of action and several cytokines have been identified as factors involved in the inflammatory process in CD, and many new molecules have been developed to treat this complex disease. New agents have been developed that target leukocyte trafficking, block or adhesion molecules for example, as well as the development of antibodies against classic inflammatory cytokines or therapies directed against IL-12/23 and Janus kinases. The development of selective mechanisms of action and targeting of different cytokines or inflammatory mediators for each patient presents the biggest challenge for the future in CD therapy. Such agents are currently at different phases of development. We aim to review the current literature data on a targeted approach in CD, which could be promising alternative approach for CD patients in the near future.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalExpert Review of Gastroenterology and Hepatology
Publication statusAccepted/In press - Feb 15 2016


  • anti-adhesion molecules
  • anti-cytokine
  • biologics
  • Crohn’s disease
  • small molecules

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Emerging therapeutic targets and strategies in Crohn’s disease'. Together they form a unique fingerprint.

Cite this